144 related articles for article (PubMed ID: 36826063)
1. Prognostic Significance of p53 and p63 in Diffuse Large B-Cell Lymphoma: A Single-Institution Experience.
Moreno JCA; Bahmad HF; Aljamal AA; Delgado R; Salami A; Guillot C; Castellano-Sánchez AA; Medina AM; Sriganeshan V
Curr Oncol; 2023 Jan; 30(2):1314-1331. PubMed ID: 36826063
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
3. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
4. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
[No Abstract] [Full Text] [Related]
5. p63 protein expression in high risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
7. Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience.
Hu WM; Jin JT; Wu CY; Lu JB; Zhang LH; Zeng J; Lin SX
Diagn Pathol; 2019 Nov; 14(1):128. PubMed ID: 31711519
[TBL] [Abstract][Full Text] [Related]
8. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].
Huang P; Chen S; Yang X; Lei YY; Xu XY; Liu YX; Guo YH; Pan Y; Wang XH; Zhang HL; Fu K; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):589-593. PubMed ID: 32397023
[No Abstract] [Full Text] [Related]
11. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
12. [Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].
Ding X; Hou SL; Li YQ; Li X; Li L; Lian K; Wang GG; Wu XB; Zhang ZH; Liu H; Wang YQ; Zhang QH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1504-1514. PubMed ID: 31607305
[TBL] [Abstract][Full Text] [Related]
13. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].
Sun GX; Cao XS; Li Q; Wang ZL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):576-81. PubMed ID: 23042398
[TBL] [Abstract][Full Text] [Related]
15. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
16. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
17. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of proteins expression by immunohistochemical method in diffuse large B cell lymphoma].
Yu WJ; Cao LH; Wang JH; Wang ZM; Qian WB; Tong HY; Meng HT; Mai WY; Mao LP; Qian JJ; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):784-788. PubMed ID: 29081196
[No Abstract] [Full Text] [Related]
20. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]